FDA Extends Review Time for Investigational Duchenne Agent Givinostat
December 15th 2023Givinostat, a histone deacetylase inhibitor from Italfarmaco, was supported by data from the phase 3 EPIDYS study, a randomized, double-blind, placebo-controlled, multicenter trial investigating the agent vs placebo.
Read More
EMBARK Data Support Delandistrogene Moxeparvovec for DMD Across All Study End Points
November 22nd 2023Over a 52-week treatment period, the gene therapy demonstrated robust evidence for a clinically meaningful benefit, including across several prespecified functional secondary end points vs placebo.
Read More
Cognitive Benefits in Multiple Sclerosis Seen After Transcranial Current Stimulation
November 17th 2023Patients with multiple sclerosis (MS) showed cognitive improvements with frontal theta-transcranial alternating current stimulation (tACS), suggesting its potential as a tolerable and beneficial intervention.
Read More
Timing of Neurofilament Light Changes May Predict Multiple Sclerosis Worsening
November 16th 2023The reported neurofilament light elevation preceding confirmed disability worsening events highlighted the value of NfL as an early biomarker of disability worsening and points to the existence of different windows of dynamic central nervous system pathology.
Read More
SDOH Lead to Greater Suboptimal Treatment Response in Myasthenia Gravis
November 3rd 2023A retrospective study presented at the 2023 American Association of Neuromuscular and Electrodiagnotsic Medicine meeting revealed that social determinants of health (SDOH) are linked to poorer treatment outcomes in patients who have myasthenia gravis, emphasizing the need for identifying and supporting at-risk individuals.
Read More
Rapid Administration of Diazepam Results in Improved Seizure Cluster Cessation, Shorter Seizures
September 29th 2023Treatment with diazepam nasal spray resulted in a statistically significant change in time between seizure clusters, potentially reflecting a beneficial effect of intermittent rescue therapy.
Read More
Super-Refractory Status Epilepticus Linked With Unknown Etiologies, High Mortality Rates
September 23rd 2023Patients treated for more than 28 days had a higher chance of status epilepticus cessation, but also a high risk of moderate to severe disability at discharge, according to one study.
Read More
Raising the Overall Awareness for Infantile Spasms, Early Recognition of Pre-Epilepsy Diagnosis
December 22nd 2022Martina Bebin, MD, MPA, professor of neurology, University of Alabama at Birmingham Epilepsy Center, discussed Infantile Spasms Awareness Week, the strides made within the field, and the emphasis on early and accurate diagnosis.
Read More